All In Biotech

Investigational drug · Phase 3

ESG401

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Metastatic Breast Cancer, Triple-Negative Breast Cancer (TNBC), Neoplasms, Breast.

Phase 3

Last checked: Nov 19, 2026Latest source record: Sep 23, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

3

2 still active

All registered trials

4

Any phase or sponsor naming "ESG401"

First trial start

2021

Sep 14, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "ESG401", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Metastatic Breast Cancer
  • Triple-Negative Breast Cancer (TNBC)
  • Neoplasms, Breast
  • Neoplasms, Lung
  • Neoplasms,Colorectal
  • Neoplasms, Bladder
  • Neoplasm of Stomach
  • Neoplasms,Ovarian

Approved drugs for the same conditions: Breast cancer · Oncology · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "ESG401" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 3 on PubMed

Also in development for Metastatic Breast Cancer

  • GiredestrantRO7197597, GDC-9545Phase 316 trials

    Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer

  • TQB2102Phase 311 trials

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors

  • AtirmociclibPF-07220060Phase 39 trials

    Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer

  • DB-1303BNT323, trastuzumab pamirtecanPhase 35 trials

    DualityBio Inc. · Metastatic Breast Cancer, HER2-positive Advanced Solid Tumor, Endometrial Cancer

  • IpatasertibRO5532961, GDC-0068Phase 35 trials

    Roche (Genentech) · Metastatic Breast Cancer, Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer, Ovarian Cancer

  • JSKN016Phase 34 trials

    Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Triple Negative Breast Cancer, Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer

  • LasofoxifeneAZU-101Phase 34 trials

    Sermonix Pharmaceuticals Inc. · Metastatic Breast Cancer, Vulvo Vaginal Atrophy (VVA), Locally Advanced or Metastatic Breast Cancer

  • TQB2930Phase 34 trials

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · HER2-positive Advanced Breast Cancer, Colorectal Cancer, Metastatic Breast Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.